146 related articles for article (PubMed ID: 29115937)
1. Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
Minichillo S; Gallelli I; Barbieri E; Cubelli M; Rubino D; Quercia S; Dall'Olio M; Rapezzi C; Zamagni C
BMC Cancer; 2017 Nov; 17(1):722. PubMed ID: 29115937
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
3. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
4. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
[TBL] [Abstract][Full Text] [Related]
5. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Martinello R; Becco P; Vici P; Airoldi M; Del Mastro L; Garrone O; Barone C; Pizzuti L; D'Alonzo A; Bellini E; Milani A; Bonzano A; Montemurro F
Breast J; 2019 May; 25(3):444-449. PubMed ID: 30932296
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
8. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
9. Comparing trastuzumab-related cardiotoxicity between elderly and younger patients with breast cancer: a prospective cohort study.
Aladwani A; Mullen A; Alrashidi M; Alfarisi O; Alterkait F; Aladwani A; Kumar A; Boyd M; Eldosouky ME
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7643-7653. PubMed ID: 34982426
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman.
Alghafar DA; Younos I; Baimani KA; Al-Salhi D; Al-Riyami A; Rizvi S; Buckley NE
J Oncol Pharm Pract; 2021 Mar; 27(2):312-321. PubMed ID: 32340535
[TBL] [Abstract][Full Text] [Related]
11. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
de Azambuja E; Ponde N; Procter M; Rastogi P; Cecchini RS; Lambertini M; Ballman K; Aspitia AM; Zardavas D; Roca L; Gelber RD; Piccart-Gebhart M; Suter T
Breast Cancer Res Treat; 2020 Jan; 179(1):161-171. PubMed ID: 31605311
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
16. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer.
Grazziotin LR; Picon PD
J Oncol Pharm Pract; 2017 Jun; 23(4):264-272. PubMed ID: 26983449
[TBL] [Abstract][Full Text] [Related]
17. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.
Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J
J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
20. Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy.
El-Sherbeny WS; Sabry NM; Sharbay RM
J Echocardiogr; 2019 Jun; 17(2):76-83. PubMed ID: 30099714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]